Skip to main content
. Author manuscript; available in PMC: 2008 Oct 1.
Published in final edited form as: Lung Cancer. 2007 Jul 3;58(1):95–103. doi: 10.1016/j.lungcan.2007.05.017

Table 1.

Characteristics of the prospective trials of gefitinib monotherapy for advanced EGFR mutation positive non-small cell lung cancers (NSCLC)

Publication source and year (reference) Gefitinib 250 mg a day treatment Number of patients (1st line/2nd line) Country of origin EGFR mutation analysis
Inoue 2006 (43) 1st line therapy (chemotherapy naive patients) 16 (16/0) Japan PCR amplification and sequence of exons 18–23
Asahina 2006 (44) 16 (16/0) Japan PCR amplification and sequence of exons 18–21
Sutani 2006 (45) Mixed 1st and subsequent lines of therapy (both patients who had received or not prior chemotherapy) 27 (4/23) Japan Peptide nucleic acid-locked nucleic acid (PNA-LNA) clamp of exons 18–21
Yoshida 2007 (46) 21 (12/9) Japan Common fragment analysis of PCR amplification for exon 19 deletions and Cycleave real-time PCR for the L858R mutation
Sunaga 2007 (47) 21 (11/10) Japan PCR amplification and sequence of exons 19–21
Total ** - 101 (59/42) Japan -

EGFR, epidermal growth factor receptor; PCR, polymerase chain reaction

*

one of the patients received both gefitinib and erlotinib

**

Another prospective study by van Zandwijk et al. [48] was exluded from this analyses due to the small number of patients that received gefitinib (n=3) and lack of survival data.